Adipose-Derived Mesenchymal Stem Cell for Preventing Biliary Complications

Inclusion Criteria * Listed for liver transplantation * Non-pediatric patients with a planned LDLT * Ability to communicate with investigative staff * Competence to give written informed consent * Ability to comply with the entire study procedure * All sexes and genders will be eligible for the study Exclusion Criteria * Planned deceased donor liver transplantation * Uncontrolled / unresolved local or systemic infection * Body mass index \> 40 * Planned pancreaticoduodenectomy or sleeve gastrectomy * Anticipation of 3 biliary anastomoses (we will include those anticipated to have 1 or 2 biliary anastomoses as detailed below) * Pregnancy or breastfeeding * Non-liver cancers (we will include certain patients with primary liver cancer as detailed below) * Treatment with any investigational drug / device within 60 days prior to study entry * Any other condition which in the judgment of the investigator would preclude adequate evaluation of the safety and efficacy of AMSCs * Patients who are employees or relatives of the investigator